Actively Recruiting
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
Led by University of California, Davis · Updated on 2024-12-18
150
Participants Needed
1
Research Sites
378 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
CONDITIONS
Official Title
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have histologically or biochemically confirmed prostate cancer, urothelial carcinoma, or renal cell carcinoma
- Provide signed and dated informed consent
- Willing to follow all study procedures and available for study duration
- Age 18 years or older at time of consent
- Currently on systemic therapy and a candidate to continue current line with no more than 30-day break for local therapy
- Have received at least 1 line of systemic therapy for metastatic disease with at least 3 months of clinical benefit before new metastatic lesions
- Have 5 or fewer progressing or new metastatic lesions
- All progressing or new lesions can be safely treated with local ablative therapies per treating specialists
You will not qualify if you...
- Medical conditions that prevent locally ablative therapies
- History of treatment-related toxicities that limit or prevent local ablative therapies
- Presence of progressing intracranial lesions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, Davis
Sacramento, California, United States, 95817
Actively Recruiting
Research Team
S
Selina Laqui
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here